Title: Scaffolded HIV-1 vaccine immunogens

Abstract

The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections.

Inventors:

Zhu, Jiang; He, Linling

Issue Date:

2020-09-22

Research Org.:

SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States)

Sponsoring Org.:

USDOE

OSTI Identifier:

1735281

Patent Number(s):

10780178

Application Number:

16/177,165

Assignee:

The Scripps Research Institute (La Jolla, CA)

Patent Classifications (CPCs):

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

A61K2039/55555 - {Liposomes
A61K2039/55561 - {CpG containing adjuvants
A61K2039/57 - {characterised by the type of response, e.g. Th1, Th2}
A61K2039/575 - {humoral response}
A61K38/162 - {from virus}
A61K39/12 - Viral antigens
A61K39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K47/646 - {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
A61K47/69 - the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K9/51 - Nanocapsules

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P31/18 - for HIV

C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES

C07K14/005 - from viruses
C07K14/162 - {env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site}

C - CHEMISTRY C12 - BIOCHEMISTRY C12N - MICROORGANISMS OR ENZYMES

C12N2740/16023 - Virus like particles [VLP]
C12N2740/16122 - New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/16134 - Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Show less

DOE Contract Number:  

AC02-76SF00515

Resource Type:

Patent

Resource Relation:

Patent File Date: 10/31/2018

Country of Publication:

United States

Language:

English

Subject:

60 APPLIED LIFE SCIENCES